Arrhythmia Research Technology Inc (HRT) 7.20 $HRT
Arrhythmia Research Technology, Inc. Reports 28.1% Revenue Growth; Delivered $0.09 in Earnings per Share for Second Quarter 2014
GlobeNewswire - Thu Aug 07, 3:44PM CDT
-- Net sales increased 28.1% over second quarter 2013 to $6.3 million; Net sales were up 16.7% year to date
Arrhythmia Research Technology Has Returned 98.4% Since SmarTrend Recommendation (HRT)
Comtex SmarTrend(R) - Tue Mar 25, 4:42PM CDT
SmarTrend identified an Uptrend for Arrhythmia Research Technology (AMEX:HRT) on December 6th, 2012 at $2.53. In approximately 16 months, Arrhythmia Research Technology has returned 98.42% as of today's recent price of $5.01.
Arrhythmia Research Technology, Inc. Announces Fourth Quarter and 2013 Year End Results
Marketwire - Fri Mar 21, 3:15PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) and its subsidiaries (the "Company"
today announced its results for the quarter and year ending December 31, 2013. The Company's financial results reflect the consolidated results of Arrhythmia Research Technology, Inc. and its subsidiaries, including Micron Products, Inc. ("Micron" , and the discontinued operations of RMDDxUSA Corp. and RMDDx Corporation (collectively "WirelessDx" .
Needing Smarter, More Cost-Effective Production, Medical OEMs Turn to Contract Manufacturing
PR Newswire - Tue Mar 11, 10:47AM CDT
Medical devices - including orthopedic implants - continue to be a key point of innovation and growth in healthcare. As this trend continues, the demand for efficient, nimble contract manufacturing will increase. To meet growing demand, contract manufacturer Micron Products, Inc., a wholly-owned subsidiary of Arrhythmia Research Technologies, Inc. (NYSE MKT: HRT), has created an integrated system for orthopedic implant manufacturing that not only leads to further innovation, but also reduces time to market, cuts costs and eliminates supply chain breaks.
Arrhythmia Research Technology Up 98.4% Since SmarTrend Uptrend Call (HRT)
Comtex SmarTrend(R) - Fri Mar 07, 9:09AM CST
SmarTrend identified an Uptrend for Arrhythmia Research Technology (AMEX:HRT) on December 6th, 2012 at $2.53. In approximately 15 months, Arrhythmia Research Technology has returned 98.41% as of today's recent price of $5.01.
Arrhythmia Research Technology, Inc. Announces Supply Agreement With Blue Belt Technologies, Inc.
Marketwire - Wed Feb 19, 1:26PM CST
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) and its subsidiary Micron Products, Inc. (the "Company" announced today that it has entered into a multi-year supply agreement with Blue Belt Technologies, Inc. (Blue Belt) to produce orthopedic implant components used in its STRIDE(TM) Unicondylar Knee system.
Arrhythmia Research Technology, Inc. Announces Date of Annual Meeting of Shareholders
Marketwire - Fri Feb 14, 8:22AM CST
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) today announced that its annual meeting of shareholders will be held on Thursday, May 22, 2014 at 10:00 a.m. at the Double Tree by Hilton Hotel, 99 Erdman Way, Leominster, Massachusetts for shareholders of record as of April 2, 2014.
OTC Daily Alert Stock Watch - Arrhythmia Research Technology, Inc. (NYSE: HRT)
WorldStockWire - Tue Sep 17, 1:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arrhythmia Research Technology Inc. Announces Resignation of CFO and Appointment of New Principal Financial Officer
Marketwire - Fri Sep 13, 7:21AM CDT
Arrhythmia Research Technology Inc. (NYSE MKT: HRT) (the "Company" announced today that the Company's Board of Directors appointed Mr. Derek T. Welch, age 45, the Company's Corporate Controller, to act as principal financial officer and accounting officer of the Company upon the resignation, effective September 12, 2013, of Mr. David A. Garrison, who served as the Company's Executive Vice President and Chief Financial Officer.
Arrhythmia Research Technology, Inc. Receives NYSE MKT LLC Exchange Compliance Notice
Marketwire - Fri Aug 23, 3:58PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT), (the "Company" announced that, on August 20, 2013, it received notice from the NYSE MKT LLC (the "Exchange" that it is not in compliance with certain of the Exchange's continued listing standards as set forth in Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" as a result of the failure to file its interim report on Form 10-Q on a timely basis. The Company has therefore become subject to the procedures and requirements of Section 1009 of the Company Guide. Such procedures require the Company to communicate with the Exchange by August 26, 2013 to confirm receipt of the letter and indicate whether or not it intends to submit a plan of compliance. The Company intends to submit a plan of compliance to the Exchange by September 3, 2013 in accordance with the notice advising the Exchange of action it has taken or intends to take that will bring the Company into compliance with Sections 134 and 1101 of the Company Guide by no later than November 14, 2013. If the plan is accepted but the Company is not in compliance with the continued listing standards of the Company Guide by November 14, 2013 or if the Company is not making progress consistent with the plan, the Company may be subject to delisting procedures.
Arrhythmia Research Technology, Inc. Announces Delay in Finalizing Second Quarter Results
Marketwire - Tue Aug 20, 9:24AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the "Company" reported today that it was unable to file its quarterly report on Form 10-Q for the three months ended June 30, 2013 within the automatic extension of its due date to August 19, 2013 afforded by its filing of a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission.
Arrhythmia Research Technology Inc posts lower net loss of USD5,671 in Q1 2013
M2 - Mon Jul 01, 7:29AM CDT
Electrocardiography software company Arrhythmia Research Technology Inc (NYSE MKT:HRT) and its subsidiaries stated on Friday its total net loss of USD5,671 (USD0.00 per share) for the quarter ending 31 March 2013.
Arrhythmia Research Technology, Inc. Announces First Quarter 2013 Results
Marketwire - Fri Jun 28, 1:18PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) and its subsidiaries (the "Company" announced today its results for the quarter ending March 31, 2013. The Company's financial results reflect the consolidated results of Arrhythmia Research Technology, Inc. and its subsidiaries, including Micron Products, Inc. ("Micron" , and the discontinued operations of RMDDxUSA Corp. and RMDDx Corporation (collectively "WirelessDx" .
Arrhythmia Research Technology, Inc. Receives NYSE MKT Exchange Compliance Notice
Marketwire - Fri May 31, 3:00PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT), (the "Company" announced that, on May 17, 2013, it received notice from the NYSE MKT LLC (the "Exchange" that it is not in compliance with certain of the Exchange's continued listing standards as set forth in Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" as a result of the failure to file its interim report on Form 10-Q on a timely basis. The Company has therefore become subject to the procedures and requirements of Section 1009 of the Company Guide. Such procedures require the Company to communicate with the Exchange by May 23, 2013 to confirm receipt of the letter and indicate whether or not it intends to submit a plan of compliance. The Company intends to submit a plan of compliance to the Exchange by May 31, 2013 in accordance with the notice advising the Exchange of action it has taken or intends to take that will bring the Company into compliance with Sections 134 and 1101 of the Company Guide by no later than August
Arrhythmia Research Technology, Inc. Announces Delay in Finalizing First Quarter of 2013 Results
Marketwire - Fri May 17, 8:01AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the "Company" reported today that it will not be able to file its quarterly report on Form 10-Q for the interim period ended March 31, 2013 within the automatic extension of its due date to May 20, 2013 afforded by its filing of a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission.
Arrhythmia Research Technology, Inc. Announces NIH-Funded Multi-Center Study Reports on Key Role of the Signal-Averaged Electrocardiogram (SAECG) in Identifying Patients at Risk of Potentially Lethal Ventricular Arrhythmias
Marketwire - Fri May 10, 10:47AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the Company) announces positive results of the Company's Signal-Averaged Electrocardiography (SAECG) technology employed in a multi-center clinical trial that studied 484 patients with prior myocardial infarction (heart attack). Twenty-two major cardiac centers including University of Rochester, Duke University, University of Pennsylvania and UMass Memorial Hospital participated in this study. The patients enrolled were considered at high risk of ventricular arrhythmias because of low ejection fraction (EF ? 35%). Patients received implantable cardiac defibrillators (ICD) as primary prevention against sudden cardiac death. The multi-center study assessed these patients for ventricular arrhythmia risk using more than ten different ECG-based diagnostic methodologies and algorithms, including 12-lead ECG, 24-hour Holter monitoring, T wave alternans and SAECG-derived parameters. From this large battery of ECG tests, only the Company's SAECG-derived low QRS w
Arrhythmia Research Technology, Inc. Announces Delay in Finalizing Fourth Quarter and 2012 Year End Results
Marketwire - Wed Apr 17, 7:15AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the "Company" reported today that it was unable to file its annual report on Form 10-K for the fiscal year ended December 31, 2012 within the automatic extension of its due date to April 16, 2013 afforded by its filing of a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission.
Arrhythmia Research Technology Inc elects Salvatore Emma Jr as CEO and president
M2 - Wed Apr 10, 8:05AM CDT
Signal-averaging electrocardiography software supplier Arrhythmia Research Technology Inc (NYSE MKT: HRT) revealed on Tuesday the appointment of Salvatore Emma Jr as its president, chief executive officer and to its board of directors.
Arrhythmia Research Technology, Inc. Reports 28.1% Revenue Growth; Delivered $0.09 in Earnings per Share for Second Quarter 2014
GlobeNewswire - Thu Aug 07, 3:44PM CDT
-- Net sales increased 28.1% over second quarter 2013 to $6.3 million; Net sales were up 16.7% year to date
Arrhythmia Research Technology Has Returned 98.4% Since SmarTrend Recommendation (HRT)
Comtex SmarTrend(R) - Tue Mar 25, 4:42PM CDT
SmarTrend identified an Uptrend for Arrhythmia Research Technology (AMEX:HRT) on December 6th, 2012 at $2.53. In approximately 16 months, Arrhythmia Research Technology has returned 98.42% as of today's recent price of $5.01.
Arrhythmia Research Technology, Inc. Announces Fourth Quarter and 2013 Year End Results
Marketwire - Fri Mar 21, 3:15PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) and its subsidiaries (the "Company"
today announced its results for the quarter and year ending December 31, 2013. The Company's financial results reflect the consolidated results of Arrhythmia Research Technology, Inc. and its subsidiaries, including Micron Products, Inc. ("Micron" , and the discontinued operations of RMDDxUSA Corp. and RMDDx Corporation (collectively "WirelessDx" . Needing Smarter, More Cost-Effective Production, Medical OEMs Turn to Contract Manufacturing
PR Newswire - Tue Mar 11, 10:47AM CDT
Medical devices - including orthopedic implants - continue to be a key point of innovation and growth in healthcare. As this trend continues, the demand for efficient, nimble contract manufacturing will increase. To meet growing demand, contract manufacturer Micron Products, Inc., a wholly-owned subsidiary of Arrhythmia Research Technologies, Inc. (NYSE MKT: HRT), has created an integrated system for orthopedic implant manufacturing that not only leads to further innovation, but also reduces time to market, cuts costs and eliminates supply chain breaks.
Arrhythmia Research Technology Up 98.4% Since SmarTrend Uptrend Call (HRT)
Comtex SmarTrend(R) - Fri Mar 07, 9:09AM CST
SmarTrend identified an Uptrend for Arrhythmia Research Technology (AMEX:HRT) on December 6th, 2012 at $2.53. In approximately 15 months, Arrhythmia Research Technology has returned 98.41% as of today's recent price of $5.01.
Arrhythmia Research Technology, Inc. Announces Supply Agreement With Blue Belt Technologies, Inc.
Marketwire - Wed Feb 19, 1:26PM CST
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) and its subsidiary Micron Products, Inc. (the "Company"
announced today that it has entered into a multi-year supply agreement with Blue Belt Technologies, Inc. (Blue Belt) to produce orthopedic implant components used in its STRIDE(TM) Unicondylar Knee system. Arrhythmia Research Technology, Inc. Announces Date of Annual Meeting of Shareholders
Marketwire - Fri Feb 14, 8:22AM CST
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) today announced that its annual meeting of shareholders will be held on Thursday, May 22, 2014 at 10:00 a.m. at the Double Tree by Hilton Hotel, 99 Erdman Way, Leominster, Massachusetts for shareholders of record as of April 2, 2014.
OTC Daily Alert Stock Watch - Arrhythmia Research Technology, Inc. (NYSE: HRT)
WorldStockWire - Tue Sep 17, 1:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arrhythmia Research Technology Inc. Announces Resignation of CFO and Appointment of New Principal Financial Officer
Marketwire - Fri Sep 13, 7:21AM CDT
Arrhythmia Research Technology Inc. (NYSE MKT: HRT) (the "Company"
announced today that the Company's Board of Directors appointed Mr. Derek T. Welch, age 45, the Company's Corporate Controller, to act as principal financial officer and accounting officer of the Company upon the resignation, effective September 12, 2013, of Mr. David A. Garrison, who served as the Company's Executive Vice President and Chief Financial Officer. Arrhythmia Research Technology, Inc. Receives NYSE MKT LLC Exchange Compliance Notice
Marketwire - Fri Aug 23, 3:58PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT), (the "Company"
announced that, on August 20, 2013, it received notice from the NYSE MKT LLC (the "Exchange" that it is not in compliance with certain of the Exchange's continued listing standards as set forth in Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" as a result of the failure to file its interim report on Form 10-Q on a timely basis. The Company has therefore become subject to the procedures and requirements of Section 1009 of the Company Guide. Such procedures require the Company to communicate with the Exchange by August 26, 2013 to confirm receipt of the letter and indicate whether or not it intends to submit a plan of compliance. The Company intends to submit a plan of compliance to the Exchange by September 3, 2013 in accordance with the notice advising the Exchange of action it has taken or intends to take that will bring the Company into compliance with Sections 134 and 1101 of the Company Guide by no later than November 14, 2013. If the plan is accepted but the Company is not in compliance with the continued listing standards of the Company Guide by November 14, 2013 or if the Company is not making progress consistent with the plan, the Company may be subject to delisting procedures. Arrhythmia Research Technology, Inc. Announces Delay in Finalizing Second Quarter Results
Marketwire - Tue Aug 20, 9:24AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the "Company"
reported today that it was unable to file its quarterly report on Form 10-Q for the three months ended June 30, 2013 within the automatic extension of its due date to August 19, 2013 afforded by its filing of a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission. Arrhythmia Research Technology Inc posts lower net loss of USD5,671 in Q1 2013
M2 - Mon Jul 01, 7:29AM CDT
Electrocardiography software company Arrhythmia Research Technology Inc (NYSE MKT:HRT) and its subsidiaries stated on Friday its total net loss of USD5,671 (USD0.00 per share) for the quarter ending 31 March 2013.
Arrhythmia Research Technology, Inc. Announces First Quarter 2013 Results
Marketwire - Fri Jun 28, 1:18PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) and its subsidiaries (the "Company"
announced today its results for the quarter ending March 31, 2013. The Company's financial results reflect the consolidated results of Arrhythmia Research Technology, Inc. and its subsidiaries, including Micron Products, Inc. ("Micron" , and the discontinued operations of RMDDxUSA Corp. and RMDDx Corporation (collectively "WirelessDx" . Arrhythmia Research Technology, Inc. Receives NYSE MKT Exchange Compliance Notice
Marketwire - Fri May 31, 3:00PM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT), (the "Company"
announced that, on May 17, 2013, it received notice from the NYSE MKT LLC (the "Exchange" that it is not in compliance with certain of the Exchange's continued listing standards as set forth in Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide" as a result of the failure to file its interim report on Form 10-Q on a timely basis. The Company has therefore become subject to the procedures and requirements of Section 1009 of the Company Guide. Such procedures require the Company to communicate with the Exchange by May 23, 2013 to confirm receipt of the letter and indicate whether or not it intends to submit a plan of compliance. The Company intends to submit a plan of compliance to the Exchange by May 31, 2013 in accordance with the notice advising the Exchange of action it has taken or intends to take that will bring the Company into compliance with Sections 134 and 1101 of the Company Guide by no later than August Arrhythmia Research Technology, Inc. Announces Delay in Finalizing First Quarter of 2013 Results
Marketwire - Fri May 17, 8:01AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the "Company"
reported today that it will not be able to file its quarterly report on Form 10-Q for the interim period ended March 31, 2013 within the automatic extension of its due date to May 20, 2013 afforded by its filing of a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission. Arrhythmia Research Technology, Inc. Announces NIH-Funded Multi-Center Study Reports on Key Role of the Signal-Averaged Electrocardiogram (SAECG) in Identifying Patients at Risk of Potentially Lethal Ventricular Arrhythmias
Marketwire - Fri May 10, 10:47AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the Company) announces positive results of the Company's Signal-Averaged Electrocardiography (SAECG) technology employed in a multi-center clinical trial that studied 484 patients with prior myocardial infarction (heart attack). Twenty-two major cardiac centers including University of Rochester, Duke University, University of Pennsylvania and UMass Memorial Hospital participated in this study. The patients enrolled were considered at high risk of ventricular arrhythmias because of low ejection fraction (EF ? 35%). Patients received implantable cardiac defibrillators (ICD) as primary prevention against sudden cardiac death. The multi-center study assessed these patients for ventricular arrhythmia risk using more than ten different ECG-based diagnostic methodologies and algorithms, including 12-lead ECG, 24-hour Holter monitoring, T wave alternans and SAECG-derived parameters. From this large battery of ECG tests, only the Company's SAECG-derived low QRS w
Arrhythmia Research Technology, Inc. Announces Delay in Finalizing Fourth Quarter and 2012 Year End Results
Marketwire - Wed Apr 17, 7:15AM CDT
Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the "Company"
reported today that it was unable to file its annual report on Form 10-K for the fiscal year ended December 31, 2012 within the automatic extension of its due date to April 16, 2013 afforded by its filing of a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission. Arrhythmia Research Technology Inc elects Salvatore Emma Jr as CEO and president
M2 - Wed Apr 10, 8:05AM CDT
Signal-averaging electrocardiography software supplier Arrhythmia Research Technology Inc (NYSE MKT: HRT) revealed on Tuesday the appointment of Salvatore Emma Jr as its president, chief executive officer and to its board of directors.
